Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Clinical trial NCT05278351 · UNKNOWN
Trial details
- NCT number
- NCT05278351
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-13
- Primary completion
- 2024-04-01
- Enrollment
- 87
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.